Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.43 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9737112 | 0.89 | TAAR1 (0.54) | TAAR1ALDH1A1CYP2D6IDO1DNM1 | |
| SCHEMBL5909429 | 0.87 | PARP1 (0.47) | ALDH1A1CYP2D6CXCR4CYP1A2CYP2C19 | |
| SCHEMBL4911510 | 0.85 | MEN1 (0.54) | TAAR1ALDH1A1CYP2D6IDO1DNM1 | |
| SCHEMBL10077141 | 0.84 | CYP2D6 (0.50) | TAAR1ALDH1A1CYP2D6IDO1DNM1 | |
| SCHEMBL4916688 | 0.83 | MEN1 (0.52) | TAAR1ALDH1A1CYP2D6IDO1DNM1 | |
| SCHEMBL4917404 | 0.83 | MEN1 (0.52) | TAAR1ALDH1A1CYP2D6IDO1DNM1 | |
| SCHEMBL5034657 | 0.83 | MEN1 (0.52) | TAAR1ALDH1A1CYP2D6IDO1DNM1 | |
| Hydrochloric Acid SCHEMBL31169759 | 0.82 | CYP2D6 (0.53) | TAAR1ALDH1A1CYP2D6IDO1DNM1 | |
| SCHEMBL15705379 | 0.82 | CHRM2 (0.50) | TAAR1ALDH1A1CYP2D6IDO1DNM1 | |
| SCHEMBL27451191 | 0.82 | TAAR1 (0.47) | TAAR1ALDH1A1CYP2D6IDO1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636787-B | Compound with Tau protein inhibition activity and preparation method thereof | 北京理工大学 | 2024-10-18 | — | — | CN | disclosed |
| EP-4139308-B1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-07-17 | — | — | EP | disclosed |
| CN-115636787-A | Compound with Tau protein inhibitory activity and preparation method thereof | 北京理工大学 | 2023-01-24 | — | — | CN | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021101919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10806726-B2 | Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitors | SAMUMED, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| EP-1732607-B1 | POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER | ASCENDIS PHARMA GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180185343-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-05 | — | — | US | disclosed |
| US-7482359-B2 | Androgen receptor modulators | MERCK & CO., INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070269405-A1 | Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2007-11-22 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | disclosed |
| CN-1662487-A | Amide linker peroxisome proliferator-activated receptor modulators | LILLY CO ELI (US) | 2005-08-31 | — | — | CN | disclosed |
| EP-1517882-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000789-A9 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004000789-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | TAAR1 4627/4885ALDH1A1 458/4885CYP2D6 189/4885 |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | TAAR1 2930/4885ALDH1A1 235/4885CYP2D6 3957/4885 |
| US-10806726-B2 | Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitors | CTNNB1, GSK3B, WNT3 | TAAR1 4506/4885ALDH1A1 3385/4885CYP2D6 2998/4885 |
| US-20070269405-A1 | Androgen Receptor Modulators | AR, SHBG, FSHR | TAAR1 3620/4885ALDH1A1 2119/4885CYP2D6 2985/4885 |
| US-20180185343-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, CTNNB1, WNT3A | TAAR1 4337/4885ALDH1A1 3226/4885CYP2D6 2435/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | TAAR1 1857/4885ALDH1A1 1322/4885CYP2D6 64/4885 |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | TAAR1 751/4885ALDH1A1 840/4885CYP2D6 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.